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Summary
Background Sleep disturbance occurs in most patients with delusions or hallucinations and should be treated as a 
clinical problem in its own right. However, cognitive behavioural therapy (CBT)—the best evidence-based treatment 
for insomnia—has not been tested in this patient population. We aimed to pilot procedures for a randomised trial 
testing CBT for sleep problems in patients with current psychotic experiences, and to provide a preliminary 
assessment of potential beneﬁ t.
Methods We did this prospective, assessor-blind, randomised controlled pilot trial (Better Sleep Trial [BEST]) at two 
mental health centres in the UK. Patients (aged 18–65 years) with persistent distressing delusions or hallucinations in 
the context of insomnia and a schizophrenia spectrum diagnosis were randomly assigned (1:1), via a web-based 
randomisation system with minimisation to balance for sex, insomnia severity, and psychotic experiences, to receive 
either eight sessions of CBT plus standard care (medication and contact with the local clinical team) or standard care 
alone. Research assessors were masked to group allocation. Assessment of outcome was done at weeks 0, 12 (post-
treatment), and 24 (follow-up). The primary eﬃ  cacy outcomes were insomnia assessed by the Insomnia Severity 
Index (ISI) and delusions and hallucinations assessed by the Psychotic Symptoms Rating Scale (PSYRATS) at week 
12. We did analysis by intention to treat, with an aim to provide conﬁ dence interval estimation of treatment eﬀ ects. 
This study is registered with ISRCTN, number 33695128.
Findings Between Dec 14, 2012, and May 22, 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 
50 patients to receive CBT plus standard care (n=24) or standard care alone (n=26). The last assessments were 
completed on Feb 10, 2015. 48 (96%) patients provided follow-up data. 23 (96%) patients oﬀ ered CBT took up the 
intervention. Compared with standard care, CBT led to reductions in insomnia in the large eﬀ ect size range at week 
12 (adjusted mean diﬀ erence 6·1, 95% CI 3·0–9·2, eﬀ ect size d=1·9). By week 12, nine (41%) of 22 patients receiving 
CBT and one (4%) of 25 patients receiving standard care alone no longer had insomnia, with ISI scores lower than the 
cutoﬀ  for insomnia. The treatment eﬀ ect estimation for CBT covered a range from reducing but also increasing 
delusions (adjusted mean diﬀ erence 0·3, 95% CI –2·0 to 2·6) and hallucinations (–1·9, –6·5 to 2·7). Three patients, 
all in the CBT group, had ﬁ ve adverse events, although none were regarded as related to study treatment.
Interpretation Our ﬁ ndings show that CBT for insomnia might be highly eﬀ ective for improving sleep in patients with 
persistent delusions or hallucinations. A larger, suitably powered phase 3 study is now needed to provide a precise 
estimate of the eﬀ ects of CBT for sleep problems, both on sleep and psychotic experiences.
Funding Research for Patient Beneﬁ t Programme, National Institute for Health Research.
Copyright © Freeman et al. Open Access article distributed under the terms of CC BY.
Introduction
Sleep problems are pervasive in people with schizo phrenia. 
In a study1 of patients with persecutory delusions, 54% had 
clinical insomnia, 30% had subthreshold insomnia, and 
only 16% were sleeping well. In outpatients with clinically 
stable schizophrenia, poor sleep is common2,3 and 
associated with an increased severity of positive symptoms.3 
Relatives of patients with schizophrenia notice sleep 
problems more than any other sign preceding relapse,4 and 
a meta-analysis5 concluded that “sleep disorders are an 
intrinsic feature of schizophrenia”. These ﬁ ndings extend 
into the general population. Findings from two national 
epidemiological studies6,7 have shown that insomnia is 
strongly associated with paranoia; additionally, sleep 
problems are associated with psychotic-like experiences in 
children.8 Yet, the treatment (or even routine assessment) 
of sleep problems in people with schizophrenia has 
received scant attention. Clinical trials in populations 
without a diagnosis of schizophrenia have shown that 
cognitive behavioural therapy (CBT) is highly eﬀ ective for 
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treatment of insomnia,9–12 and CBT is considered by many 
as the recommended treatment for this disorder.13 However, 
this therapy is yet to be tested in a randomised controlled 
trial in patients with schizophrenia.
Treatment of sleep problems in patients with psychosis 
might have another important beneﬁ t: reductions in 
delusions and hallucinations. Sleep disturbance is 
increasingly recognised as a potential contributory factor 
to the occurrence of a wide range of mental health 
problems.14,15 Sleep disturbance might also have a role in 
the occurrence of psychotic experiences such as delusions 
and hallucinations. Findings from longitudinal studies 
have shown that insomnia predicts new inceptions of 
paranoia16 and its persistence.17 Insomnia increases 
negative aﬀ ect, anomalous perceptions, and reasoning 
errors, which are all factors implicated in the development 
of persecutory ideation. Studies have also linked insomnia 
and hallucinatory experiences.18,19 In adolescents at an 
ultra-high risk of psychosis, sleep diﬃ  culties are a 
predictor of positive psychotic experiences.20 Importantly, 
research in twins has shown  overlap in the genetic and 
environmental causes of insomnia and psychotic 
experiences.18 If a causal link does exist, the clinical 
implication is that treatment of insomnia in patients with 
schizophrenia could lessen psychotic experiences, which 
would provide a new treatment route for these patients.
In a case series,21 we used CBT for insomnia in 
15 patients with persistent persecutory delusions in the 
context of non-aﬀ ective psychosis. After the brief CBT 
intervention, we recorded large reductions in levels of 
insomnia and paranoia. We also recorded signiﬁ cant 
reductions in levels of hallucinations, anxiety, and 
depression. A methodologically rigorous assessment is 
now needed. We planned the Better Sleep Trial (BEST) as 
a randomised controlled pilot trial assessing treatment of 
insomnia in patients with persistent delusions or 
hallucinations. We followed the recommendation of Lee 
and colleagues22 that “pilot studies are more about 
learning than conﬁ rming: they are not designed to 
formally assess evidence of beneﬁ t”. As such, we aimed 
to establish recruitment and follow-up rates, indicate 
levels of compliance with the treatment, examine the use 
of sleep assessments in this population, and provide an 
estimation of the potential eﬃ  cacy of the intervention.
The study is part of our process of improving treat-
ments for patients with delusions and hallucinations, 
translating advances in understanding into intervention. 
One putative causal factor at a time is targeted and the 
eﬀ ect on the psychotic experiences examined23—a so-
called interventionist-causal model approach.24 Our 
intention was to use clinical techniques focused on sleep 
and then examine the subsequent eﬀ ects. In this 
mechanistic approach, the central need is to establish 
change in the putative causal factor (ie, sleep) in one 
group compared with a group in which sleep patterns 
remain relatively stable. Therefore, the appropriate 
design was to compare the targeting of sleep with 
standard care. Identiﬁ cation of the active ingredients of 
intervention was not the question that the trial was 
designed to address.
We had two primary outcome hypotheses: that CBT for 
insomnia added to standard care would improve sleep in 
patients with psychosis compared with standard care 
alone, and that CBT for insomnia added to standard care 
would reduce delusions and hallucinations compared 
with standard care alone. Our secondary hypotheses were 
that improvements in sleep and psychotic symptoms 
would be maintained over at least 3 months, that 
improvement in sleep would be associated with improve-
ments in psychotic symptoms, and that CBT for insomnia 
would lead to improvements in other outcomes, such as 
patient wellbeing and feelings of fatigue.
Research in context
Evidence before this study
We searched PubMed and the ISRCTN trial registry up to April 
10, 2015, with the terms “insomnia”, “therapy”, and 
“schizophrenia”, without date restrictions, for English-language 
publications of randomised controlled trials investigating the 
treatment of insomnia with patients with schizophrenia. We did 
not ﬁ nd any randomised trials of treatment of insomnia in 
schizophrenia with a psychological therapy. Apart from our own 
case report series, we did not ﬁ nd any descriptions of cognitive 
behavioural therapy (CBT) for insomnia with patients with 
schizophrenia. Three further searches with the terms “insomnia”, 
“randomized”, “schizophrenia”, and “hypnotics/benzodiazepine/
melatonin”, and reading of review papers, identiﬁ ed only three 
small randomised controlled trials testing the short-term eﬀ ects 
of melatonin and eszopiclone. We found no randomised 
controlled trials assessing treatment of insomnia in patients 
selected for having current delusions and hallucinations.
Added value of this study
Our trial is the ﬁ rst randomised controlled trial to treat 
insomnia in patients with current psychotic experiences, use a 
psychological treatment for insomnia with patients with 
schizophrenia, and examine eﬀ ects of an insomnia treatment 
for patients with schizophrenia for up to 6 months. Our 
ﬁ ndings show that CBT for insomnia is likely to be beneﬁ cial for 
reducing insomnia in patients with schizophrenia.
Implications of all the available evidence
Trial data are insuﬃ  cient for the treatment of sleep problems in 
patients with schizophrenia. The present study, in combination 
with studies of CBT for insomnia in other disorders, suggests 
that CBT could be oﬀ ered as psychological treatment for 
patients with schizophrenia. However a larger, suitably 
powered phase 3 study is indicated. 
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Methods
Study design and patients
We did this prospective, assessor-blind, randomised 
controlled pilot study at two centres in the UK: Oxford 
Health National Health Service (NHS) Foundation 
Trust—a large mental health service covering a 
population of roughly 1·2 million people—and, in the 
ﬁ nal 4 months of recruitment, at an additional site at 
Northamptonshire Healthcare NHS Foundation Trust. 
We sought to include patients who had persistent, 
distressing delusions or hallucinations in the context of 
non-aﬀ ective psychosis and insomnia. Inclusion criteria 
were current delusion or hallucination; a score of at least 
2 on the distress items of the Psychotic Symptoms Rating 
Scale (PSYRATS)25 for either a delusion or hallucination; 
delusion or hallucination that had persisted for at least 
3 months; a clinical diagnosis of schizophrenia, 
schizoaﬀ ective disorder, or delusional disorder (ie, a 
diagnosis of non-aﬀ ective psychosis); sleep diﬃ  culties 
lasting 1 month or longer and a score of 15 or more on 
the Insomnia Severity Index26 (ISI; ie, clinical insomnia); 
an age of 18–65 years; and a medication dosage that had 
been stable for at least the past month. Exclusion criteria 
were a primary diagnosis of sleep apnoea, alcohol or 
substance dependency, organic syndrome or learning 
disability, a command of spoken English inadequate for 
engagement in therapy, and current engagement in 
individual CBT. Patient enrolment was done by one full-
time graduate psychologist (RL).
The trial received ethics approval from the NHS 
Research Ethics Committee South Central–Oxford C 
(reference 12/SC/0138) and the protocol has been 
published elsewhere.27 All patients provided written 
informed consent.
Randomisation and masking
We randomly assigned patients (1:1), via a web-based 
randomisation system, to receive either CBT plus 
standard care or standard care alone. The randomisation 
system was designed to balance three variables with a 
non-deterministic minimisation algorithm: sex (male vs 
female), severity of sleep problem (moderate [ISI score 
15–21] vs high [22–28]), and psychotic experiences 
(hallucination only vs delusion only vs hallucinations and 
delusions).
Research assessors (RL for most of the trial, with the 
last follow-up assessments completed by a replacement 
graduate psychologist [JM]) were masked to group 
allocation; the trial therapists informed patients of 
the randomisation outcome to maintain allocation 
concealment. Precautionary strategies to prevent un-
masking included the therapist and assessor con sidering 
room use and booking arrangements; patients being 
reminded by the assessor not to talk about treatment 
allocation; and, after the initial assessment, the assessor 
not looking at the patient’s clinical notes. In the case of 
an allocation being revealed, we remasked by using 
another assessor (which happened six times in total, 
three times at each follow-up point). All assessments 
were therefore done blind to allocation.
Procedures
The CBT intervention was provided one to one by 
clinical psychologists (EM and FW), either in NHS 
clinics or at the patient’s home. DF and HS did weekly 
clinical supervision. The aim was to provide the 
insomnia intervention in about eight sessions over 
12 weeks, with four sessions deﬁ ned as a minimum 
therapeutic dose, with ﬂ exibility in length and number 
of sessions as appropriate in this clinical group. We 
also included telephone calls and texts between sessions 
to maintain treatment momentum. The main tech-
niques standard for CBT sleep interventions were taken 
from four main sources.28–31 The intervention was 
written in a manual to guide the work, which was 
shared with the patient. Initially the sessions focused 
Figure: Trial proﬁ le
ISI=Insomnia Severity Index. PSYRATS=Psychotic Symptoms Rating Scale. CBT=cognitive behavioural therapy.
192 patients referred
106 screened for eligibility
86 excluded
83 declined to be screened
3 because of high forensic risk
56 excluded
15 had an insuﬃcient score on ISI
26 had PSYRATS scores below the cutoﬀ for current 
distressing delusion or hallucination
1 had insuﬃcient capacity to consent
9 excluded (ie, alcohol or substance dependence,  
cognitive deﬁcit, organic syndrome,  
or learning disability)
1 had a command of English that was inadequate
to engage in psychological therapy
2 were undergoing current individual CBT
2 declined to participate
50 randomly assigned
24 allocated to CBT plus standard care
23 received CBT intervention
1 did not receive CBT intervention
26 allocated to standard care alone
26 received standard care alone
22 completed 12 week assessment
2 missed 12 week assessment
23 completed 24 week assessment
1 missed 24 week assessment
25 completed 12 week assessment
1 missed 12 week assessment
25 completed 24 week assessment
1 missed 24 week assessment
24 included in intention-to-treat analysis 26 included in intention-to-treat analysis
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on psycho-education about sleep diﬃ  culties, assess-
ment of the triggering and maintenance of sleep 
diﬃ  culties, and goal setting. We used a checklist of 
factors likely to cause sleep diﬃ  culties, which was 
generated by the team. On the basis of the assessment, 
the active therapeutic techniques used could have 
included stimulus control therapy (eg, setting of 
appropriate and regular sleep times, ensuring the bed 
or bedroom were used only for sleeping, not staying in 
bed if unable to sleep for longer than 20–30 min, 
reducing sleep in the daytime), establishment of 
appropriate daytime activity and circadian rhythms (eg, 
obtaining natural light in the morning, regular 
mealtimes, gradually shifting sleep and wake times for 
sleep-phase problems), sleep hygiene, relaxation, and 
cognitive techniques addressing unhelpful beliefs and 
attitudes about sleep. The intervention was deliberately 
simpliﬁ ed, with the principal therapeutic techniques 
being stimulus control (ie, learning to associate bed 
with sleep) and improvement of daytime activity levels. 
A detailed description of our approach to treatment of 
sleep problems in this group is available elsewhere,32 
and includes noting of adaptations needed for the 
particular problems of delusions and hallucinations 
interfering with sleep, attempts to sleep being overused 
by patients as an escape from voices, extensive 
disruption of circadian rhythms, insuﬃ  cient daytime 
activity, and fear of the bed based on past adverse 
experiences. Sessions were taped with patient 
agreement. To assess treatment ﬁ delity, six tapes, 
chosen at random, were rated on the Cognitive Therapy 
Scale–Revised33 by an independent clinical psychologist 
experienced in CBT for psychosis. All tapes were rated 
as providing at least satisfactory cognitive therapy (ie, 
an average score of at least three on scale items). 
Standard care was delivered according to national and 
local service protocols and guidelines and mainly 
consisted of antipsychotic medication and contact with 
the local clinical team. We recorded medication and 
hospital admissions from clinical notes and other 
service provision using a modiﬁ ed version of the Client 
Service Receipt Inventory.34 In the baseline assessment, 
the trial patients were also assessed for insomnia using 
the Duke Structured Interview Schedule for Sleep 
Disorder Diagnoses.35
Outcomes
As a pilot study, our main outcomes concerned the 
number of participants who were recruited, complied 
with treatment, and followed up. The prespeciﬁ ed 
primary outcome measures were levels of insomnia, 
assessed with the ISI,26 and levels of delusions and 
hallucinations, assessed with the PSYRATS.25 Higher 
scores on these measures indicate greater severity.
Secondary outcome measures assessed sleep using 
diﬀ erent methods: a second self-report questionnaire 
measure of sleep (Pittsburgh Sleep Quality Index [PSQI]),36 
a sleep diary, and actigraphy data obtained by participants 
wearing an actiwatch (CamNtech MotionWatch 8, 
CamNtech, Cambridge, UK) for at least 7 days. Additionally, 
we assessed secondary outcome measures for psychiatric 
symptoms: a self-report measure of paranoid thinking 
(Paranoid Thoughts Scale);37 a standard psychiatric 
interviewer-rated assessment (the Positive and Negative 
Syndromes Scale; PANSS);38 and an adapted patient 
reported outcome measure (CHoice of Outcome In Cbt for 
psychosEs),39 which assessed, for example, self-conﬁ dence, 
peace of mind, and a sense of being in control. Other 
secondary outcomes were fatigue (Multidimensional 
Fatigue Inventory),40 quality of life (Euroqol 5 Dimensions 5 
Levels; responses were converted into a single summary 
measure using UK population tariﬀ s),41 and psychological 
wellbeing (Warwick-Edinburgh Mental Well-being Scale).42 
CBT group (n=24) Standard care alone 
group (n=26)
Age (years) 39·6 (11·6) 42·2 (13·5)
Sex
Male 16 (67%) 18 (69%)
Female 8 (33%) 8 (31%)
Ethnic origin
White 22 (92%) 25 (96%)
Black 1 (4%) 1 (4%)
Chinese 1 (4%) 0
Employment status
Unemployed 21 (88%) 23 (88%)
Part-time employed 1 (4%) 0
Full-time employed 0 1 (4%)
Volunteer 1 (4%) 1 (4%)
Retired 1 (4%) 0
Student 0 1 (4%)
Clinical diagnosis
Schizophrenia 16 (67%) 17 (65%)
Schizoaﬀ ective disorder 5 (21%) 5 (19%)
Delusional disorder 0 0
Psychosis not otherwise speciﬁ ed 3 (13%) 4 (15%)
Severity of insomnia (ISI)
Moderate (15–21) 19 (79%) 19 (73%)
High (22–28) 5 (21%) 7 (27%)
Presence of psychotic experiences
Both delusions and hallucinations 18 (75%) 19 (73%)
Delusion only 4 (17%) 3 (12%)
Hallucination only 2 (8%) 4 (15%)
Depression (BDI)
None (0–13) 3 (13%) 3 (12%)
Mild (14–19) 5 (21%) 3 (12%)
Moderate (20–28) 2 (8%) 6 (23%)
Severe (29–63) 14 (58%) 14 (54%)
Data are mean (SD) or n (%), unless otherwise indicated. CBT=cognitive behavioural therapy. ISI=Insomnia Severity 
Index. BDI=Beck Depression Inventory.
Table 1: Baseline demographic and clinical characteristics 
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We included several measures, such as the Beck Depression 
Inventory (BDI),43 for the purposes of potential mediation 
analysis. The outcome measures were completed at weeks 0 
(baseline), 12 (post-intervention), and 24 (follow-up).
During the trial, we recorded any adverse event that 
came to our attention. Medical notes were also checked 
at the end of the trial for the following events prespeciﬁ ed 
as adverse: all deaths, suicide attempts, serious violent 
incidents, admissions to secure units, formal complaints 
about therapy.
Statistical analysis
The trial statisticians (LC and L-MY) prepared a fully 
detailed statistical analysis plan and the chief 
investigator (DF) approved the plan before any analysis. 
No formal sample size calculation was done for this 
pilot study. However, the target sample size was based 
on recruitment for 15 months at an estimated rate of 
four patients per month with one research worker (ie, 
60 patients), which was considered adequate to obtain 
reasonably reliable sample size estimates.44 Outcomes 
were assessed separately for assessment points at weeks 
12 and 24. We used ANCOVA to obtain estimates and 
95% CIs of continuous outcomes, with adjustment for 
baseline variables. The analysis plan did not include 
reporting of p values, in accordance with recom-
mendations that “The analysis of a pilot study should be 
mainly descriptive or should focus on conﬁ dence 
interval estimation.”45 As a sensitivity analysis, we 
controlled for initial overall symptom severity as 
assessed by the PANSS and use of antipsychotic 
medication. In a post-hoc analysis for the main 
outcomes, we constructed a mixed model to incorporate 
the repeated measures at the two assessments (weeks 12 
and 24) for each patient. We calculated eﬀ ect sizes with 
Cohen’s d by taking the estimated coeﬃ  cient of 
treatment allocation from the ANCOVA divided by the 
pooled baseline SD. An eﬀ ect size of 0·3 is considered a 
small eﬀ ect, 0·5 a medium eﬀ ect, and 0·8 or higher a 
large eﬀ ect. We used correlation coeﬃ  cients to examine 
potential associations between changes in sleep and 
changes in psychotic experiences (changes in scores for 
each measure were calculated as week 12 score minus 
baseline score). All main analyses were done at the end 
of the last follow-up assessments (ie, there were no 
interim analyses) and were based on the intention-to-
treat population. Analyses were done with SAS 
(version 9.3)46 and were repeated by an independent 
statistician. This study is registered with ISRCTN, 
number 33695128.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. DF, L-MY, and LC had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results 
The ﬁ gure shows the trial proﬁ le. Between Dec 14, 2012, 
and May 22, 2013, and Nov 7, 2013, and Aug 26, 2014, 
we randomly assigned 50 patients to receive CBT plus 
standard care (n=24) or standard care alone (n=26), 
with the break in enrolment due to employment of a 
new trial therapist. 47 (94%) patients were from Oxford 
Health and three (6%) were from Northamptonshire 
Healthcare. The last assessments were completed on 
Feb 10, 2015. All 50 patients completed the baseline 
assessment. 48 (96%) patients provided follow-up data 
for the primary eﬃ  cacy measures (ﬁ gure). In the CBT 
group, the mean number of sessions received was 
7·3 (SD 1·9). On the basis of at least four CBT sessions 
constituting a minimum therapeutic dose, 23 (96%) of 
24 patients had a dose of the intervention. The actual 
number of treatment sessions attended in the 12 week 
period was three (n=1), four (n=1), ﬁ ve (n=1), six (n=4), 
seven (n=5), eight (n=7), nine (n=2), ten (n=2), or 
11 (n=1) sessions. The appendix shows descriptive 
comments about the intervention received from ﬁ ve of 
the ﬁ rst seven patients who had CBT.
Baseline and demographic characteristics were similar 
between groups (table 1). In line with other studies of 
persistent psychotic experiences, both groups included 
slightly more men, the average age was about 40 years, 
most participants were unemployed, and the main 
diagnosis was schizophrenia (table 1). There were high 
levels of depression in both groups (table 1), although 
BDI scores were not signiﬁ cantly correlated with level of 
insomnia at baseline (r=0·07, p=0·623). All but one 
patient (in the standard care alone group) met the Duke 
Structured Interview Schedule for Sleep Disorder 
See Online for appendix
 CBT group Standard care alone group
n Mean (SD) n Mean (SD)
Antipsychotic medication (chlorpromazine equivalent dose, mg/day)
Baseline 24 363·7 (266·5) 26 495·8 (358·1)
12 weeks 23 359·8 (289·3) 25 530·7 (366·0)
24 weeks 23 372·5 (302·9) 25 531·3 (373·2)
6 months before the trial (n)
Psychiatric hospital admission 24 0·1 (0·3) 26 0·1 (0·3)
Psychiatrist meetings 23 1·2 (1·4) 26 2·5 (4·9)
Meetings with community psychiatric nurse 23 11·7 (13·6) 26 15·4 (16·2)
Visits to day-care centre 23 6·0 (14·8) 26 2·0 (6·8)
Meetings with general practitioner 22 2·8 (3·6) 25 3·0 (5·3)
6 months during the trial (n)
Psychiatric hospital admission 24 0·1 (0·3) 26 0·1 (0·3)
Psychiatrist meetings 19 1·1 (0·9) 24 2·3 (3·9)
Meetings with community psychiatric nurse 19 7·6 (8·2) 24 13·5 (13·9)
Visits to day-care centre 19 6·1 (18·6) 24 7·9 (24·9)
Meetings with general practitioner 18 3·5 (3·9) 24 3·2 (3·2)
Table 2: Provision of standard care
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Diagnoses criteria for insomnia disorder. Provision of 
standard care was similar between groups and was fairly 
stable during the trial (table 2). All but four participants 
(n=3 given CBT, n=1 given standard care alone) were 
taking antipsychotic medication (table 2). Most 
participants were also prescribed a hypnotic, anxiolytic, 
or antidepressant medication (19 [79%] in the CBT group, 
21 [81%] in the standard care alone group; appendix). All 
participants were outpatients. 
Compared with standard care alone, CBT had a 
treatment beneﬁ t on insomnia in the large eﬀ ect size 
range at 12 weeks (table 3). Beneﬁ ts were still apparent 
at 24 weeks’ follow-up (table 2). At baseline, no patients’ 
ISI scores were lower than the cutoﬀ  indicating normal 
sleep (a score of 0–7). By week 12, nine (41%) of 
22 patients in the CBT group and one (4%) of 25 patients 
in the standard care alone group scored less than this 
cutoﬀ . The wide conﬁ dence intervals for the eﬀ ects of 
CBT on delusions and hallucinations cover a range from 
decreasing to increasing psychotic experiences (table 3). 
Changes in the other sleep assessments were relatively 
consistent with those for the primary outcome measure 
of insomnia (table 3). We recorded moderate to large 
eﬀ ect sizes in sleep quality as assessed by the PSQI 
(table 3). Data collection was less complete for the sleep 
diaries and actigraphy than for the other secondary 
outcome measures, and the ensuing eﬀ ect sizes were 
small to moderate (table 3). Compared with standard 
care alone, patients reported reduced fatigue at week 12, 
and improved quality of life and psychological wellbeing 
at week 24, with small to medium eﬀ ect sizes overall for 
both these categories (table 3). The conﬁ dence intervals 
for paranoia and overall psychiatric symptomatology 
again span CBT potentially reducing or increasing these 
problems (table 3). Correlations between changes in 
insomnia and changes in hallucinations and paranoia 
(although not PSYRATS delusions) were mainly small 
and positive, but the conﬁ dence intervals are wide and 
include negative correlations (appendix).
All the notes of the trial patients were checked. Four 
patients were admitted to hospital during the trial (n=2 
in each group; appendix). There were no deaths or 
complaints about therapy. Three patients, all in the CBT 
group, had a total of ﬁ ve adverse events: two suicide 
attempts, two serious violent incidents, and one 
admission to a secure unit (following one of the violent 
incidents). No adverse events were considered to be 
related to study treatment.
The appendix shows results of the sensitivity analysis. 
Results of the post-hoc analysis using a mixed model for 
repeated measures analysis were similar to those 
obtained using ANCOVA (appendix).
Discussion
This is the ﬁ rst randomised controlled trial testing the 
eﬀ ects of CBT for insomnia in patients with current 
psychotic experiences, which comprised very long-
standing insomnia, delusions, and hallucinations. 
Overall our study shows the feasibility of testing the 
psychological treatment adapted for this population: it 
CBT group Standard care alone 
group
Adjusted mean 
diﬀ erence 
(95% CI)
Eﬀ ect 
size (d)
n Mean (SD) n Mean (SD)
Primary outcome measure
Insomnia (ISI)
0 weeks 24 18·6 (3·2) 26 18·8 (3·3) ·· ··
12 weeks 22 9·3 (5·5) 25 15·4 (5·4) 6·1
(3·0 to 9·22)
1·9
24 weeks 23 11·0 (5·6) 25 15·0 (5·7) 3·9
(0·9 to 6·8)
1·2
Delusions (PSYRATS)
0 weeks 24 16·1 (3·2) 26 15·3 (4·9) ·· ··
12 weeks 22 13·9 (4·8) 25 13·8 (4·1) 0·3
(–2·0 to 2·6)
0·1
24 weeks 23 14·0 (4·7) 25 12·7 (5·7) –0·8
(–3·6 to 2·1)
–0·2
Hallucinations (PSYRATS)
0 weeks 24 25·1 (12·1) 26 26·7 (9·2) ·· ··
12 weeks 22 27·5 (9·2) 25 25·9 (8·1) –1·9
(–6·5 to 2·7)
–0·2
24 weeks 23 24·6 (11·6) 25 22·0 (10·2) –3·4
(–9·2 to 2·3)
–0·3
Sleep secondary outcome measures
Sleep quality (PSQI)
0 weeks 23 11·9 (3·2) 23 11·6 (2·9) ·· ··
12 weeks 21 8·7 (3·8) 23 10·5 (4·8) 1·9
(–0·4 to 4·1)
0·6
24 weeks 23 6·9 (4·4) 23 9·6 (4·8) 2·8
(0·2 to 5·4)
0·9
Time to sleep onset (min)*
0 weeks 21 61·5 (51·4) 25 61·1 (32·7) ·· ··
12 weeks 22 34·6 (40·3) 19 46·6 (37·0) 18·3
(–1·5 to 38·2)
0·4
24 weeks 20 33·3 (29·6) 21 57·9 (41·7) 26·4
(2·5 to 50·3)
0·6
Total sleep time (min)*
0 weeks 18 393·7 (127·8) 21 403·4 (146·3) ·· ··
12 weeks 17 456·4 (107·7) 18 437·5 (118·1) 33·0
(–17·9 to 83·8)
0·2
24 weeks 18 465·9 (117·1) 20 412·4 (128·2) 46·6
(–15·1 to 108·3)
0·3
Waking in night (min)*
0 weeks 19 43·5 (40·2) 22 59·1 (63·3) ·· ··
12 weeks 18 19·9 (22·2) 18 47·6 (52·1) 16·9
(–4·7 to 38·5)
0·3
24 weeks 18 32·7 (35·7) 20 42·7 (46·6) 14·6
(–11·1 to 40·3)
0·3
Total sleep time (min)†
0 weeks 20 396·3 (141·7) 23 470·0 (128·7) ·· ··
12 weeks 18 406·2 (100·0) 19 471·0 (124·4) –15·5
(–78·9 to 47·9)
–0·1
24 weeks 18 445·1 (86·7) 21 449·8 (141·1) 33·1
(–27·0 to 93·3)
0·2
(Table 3 continues on next page)
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was possible to recruit patients to the trial, to randomise 
them, to keep assessors masked to allocation, to retain 
patients in the trial, to assess a wide range of measures, 
and to implement the treatment. Indeed, there was a 
very low dropout rate for the trial assessments and a 
very high uptake of CBT. Our ﬁ ndings also show that 
CBT for insomnia, a relatively brief intervention, is 
likely to have substantial beneﬁ ts in improving sleep 
for patients with current delusions and hallucinations. 
Beneﬁ ts in sleep were sustained up to the ﬁ nal follow-
up assessment.
Findings from a qualitative study47 of a subsample of 
the trial participants are consistent with those of the 
present quantitative analysis. Our results compare well 
with the only randomised controlled trial that we are 
aware of that targeted insomnia in patients with 
schizophrenia with one of the commonly prescribed 
sedative hypnotics (so-called Z-drugs). In a randomised 
double-blind trial48 done over 8 weeks in 39 clinically 
stable outpatients with schizophrenia who had insomnia 
but were not recruited for current psychotic experiences, 
eszoplicone was compared with placebo. The medication 
led to a decrease in ISI scores of 3·78 (95% CI 0·2–7·5) 
versus placebo. The reduction in ISI score in the present 
study is very similar to that reported in a meta-analysis 
of CBT for comorbid insomnia for patients with physical 
or psychiatric disorders (ISI mean change 6·4 
[SE 1·27]).11 Our trial did not prove informative about 
the potential eﬀ ect of the sleep treatment on the 
psychotic experiences. The wide conﬁ dence intervals 
include the possibility that the treatment can either 
reduce or increase delusions and hallucinations. A 
larger trial will provide a better estimate of the eﬀ ects on 
psychotic experiences.
The clear caution when discussing potential clinical 
eﬀ ects is that this study was a pilot study. Our trial is 
insuﬃ  ciently powered to detect anything but the largest 
eﬀ ect sizes. There was no formal power calculation 
because we did not primarily intend to detect treatment 
eﬀ ects. We did not achieve the target sample size of 
60 patients, but this information will form part of the 
recruitment strategy plan for the future phase 3 trial. 
Our main purpose was to assess the feasibility of the 
assessment and to reﬁ ne procedures. A key observation 
was the wide variety of sleep disturbance within the 
patient group, including patients going to bed early in 
the evening and simply lying awake for hours, patients 
not having a bed, patients having an association with 
their bed as a place of trauma, patients awake and pacing 
all night, patients’ sleep being disturbed through the use 
of hypnotics, patients being drowsy and oversleeping at 
various times of the day, and patients only going to bed 
in the early hours (delayed-phase sleep), whereas others 
had obviously irregular sleep–wake patterns. Our 
treatment manual will become more speciﬁ c to each of 
these types of presentation and it would be of interest to 
establish whether they are associated with diﬀ erent 
outcomes. Such presentations are consistent with 
evidence of varied circadian rhythm dysfunction in 
patients with schizophrenia49 and, indeed, the complexity 
of sleep disturbance beyond insomnia in other disorders 
such as bipolar disorder.50 Notably, our trial did not 
include polysomnography. Obvious practical diﬃ  culties 
exist in implementation of such a measurement, and 
subjective reports of problems must be the key clinical 
priority. Instead of polysomnography we used actigraphy 
to assess sleep–wake timing and fragmentation. This 
CBT group Standard care alone 
group
Adjusted mean 
diﬀ erence 
(95% CI)
Eﬀ ect 
size (d)
n Mean (SD) n Mean (SD)
(Continued from previous page)
Psychiatric secondary measures
Paranoia (GPTS)
0 weeks 24 90·8 (28·7) 26 90·5 (29·8) ·· ··
12 weeks 22 89·6 (36·8) 24 96·2 (37·3) 6·7
(–10·2 to 23·5)
0·2
24 weeks 20 78·3 (34·8) 25 88·1 (35·0) 9·8
(–7·5 to 27·2)
0·3
Total symptoms (PANSS)
0 weeks 24 83·6 (16·2) 26 79·7 (14·1) ·· ··
12 weeks 22 77·5 (12·1) 24 79·3 (14·6) 3·4
(–2·3 to 9·0)
0·2
24 weeks 21 74·8 (14·7) 24 75·8 (11·8) 3·3
(–2·9 to 9·5)
0·2
Fatigue (MFI)
0 weeks 23 43·8 (16·4) 26 47·6 (15·3) ·· ··
12 weeks 22 29·1 (19·0) 24 45·4 (19·6) 10·5
(2·1 to 18·9)
0·7
24 weeks 21 25·9 (21·4) 25 38·4 (18·1) 9·0
(–1·1 to 19·1)
0·6
Patient outcomes (CHOICE)
0 weeks 23 52·2 (21·1) 26 55·0 (14·4) ·· ··
12 weeks 22 58·0 (22·7) 24 49·9 (18·3) 8·5
(–1·4 to 18·5)
0·5
24 weeks 21 60·0 (22·8) 23 57·5 (21·8) 3·8
(–7·3 to 14·9)
0·2
Quality of life (EQ-5D-5L)
0 weeks 24 0·55 (0·23) 26 0·60 (0·22) ·· ··
12 weeks 22 0·63 (0·25) 24 0·55 (0·22) 0·11
(0·02 to 0·23)
0·5
24 weeks 22 0·63 (0·27) 25 0·58 (0·20) 0·08
(–0·05 to 0·21)
0·4
Wellbeing (WEMWBS)
0 weeks 24 35·3 (9·3) 26 37·0 (7·8) ·· ··
12 weeks 22 36·1 (10·7) 24 34·0 (8·9) 2·6
(–2·1 to 7·4)
0·3
24 weeks 21 39·4 (9·9) 25 34·7 (7·9) 4·8
(–0·5 to 9·3)
0·6
CBT=cognitive behavioural therapy. ISI=Insomnia Severity Index. PSYRATS=Psychotic Symptoms Rating Scale. 
PSQI=Pittsburgh Sleep Quality Index. GPTS=Green et al Paranoid Thought Scales. PANSS=Positive and Negative Syndromes 
Scale. MFI=Multidimensional Fatigue Inventory. CHOICE=CHoice of Outcome In Cbt for psychoses. EQ–5D=Euroqol 5 
Dimensions 5 Levels. WEMWBS=Warwick-Edinburgh Mental Well-being Scale. *Sleep diary. †Actigraphy data.
Table 3: Scores for the primary and secondary outcome measures 
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